A recent review article by Hoashi et al. on molecular mechanisms and targeted therapies of BCC emphasizes the role of the melanocortin 1 receptor, MC1R, stating that several studies have reported that the risk of BCC is associated with MC1R mutations [39,40,41,42]. This evidence concerns the gene MC1R and skin basal cell carcinoma.